February 13, 2017 / 11:55 PM / 5 months ago

BRIEF-Gilead presents new phase 2 data on Bictegravir

1 Min Read

Feb 13 (Reuters) - Gilead Sciences Inc :

* Gilead presents new phase 2 data on Bictegravir, an investigational integrase strand transfer inhibitor for the treatment of HIV

* Bictegravir in combination with FTC/TAF showed 97 percent rates of virologic suppression in phase 2 study

* Gilead Sciences - phase 3 studies evaluating a single tablet HIV regimen of Bictegravir and FTC/TAF now fully enrolled; data expected later this year Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below